Neuropsychological outcomes following HSCT in MS: A Systematic Review DOI
Laura Davenport,

Mathew McCauley,

Erin Breheny

et al.

Multiple Sclerosis and Related Disorders, Journal Year: 2024, Volume and Issue: 88, P. 105702 - 105702

Published: June 5, 2024

Language: Английский

Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation DOI
Georgios Gakis, Ioannis Angelopoulos,

Ioannis Panagoulias

et al.

Autoimmunity Reviews, Journal Year: 2023, Volume and Issue: 23(2), P. 103480 - 103480

Published: Nov. 25, 2023

Language: Английский

Citations

5
Autologous Hematopoietic Stem Cell Transplantation to Treat Multiple Sclerosis DOI
Lindsay Ross,

Lisa M. Stropp,

Jeffrey A. Cohen

et al.

Neurologic Clinics, Journal Year: 2023, Volume and Issue: 42(1), P. 165 - 184

Published: July 16, 2023

Language: Английский

Citations

4
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis DOI Creative Commons
Alice Mariottini,

Chiara Nozzoli,

Ilaria Carli

et al.

Neurological Sciences, Journal Year: 2024, Volume and Issue: 45(7), P. 3379 - 3387

Published: Jan. 26, 2024

Abstract Background Autologous haematopoietic stem cell transplantation (AHSCT) is a highly effective one-off treatment for relapsing–remitting multiple sclerosis (RR-MS), potentially representing an optimal front-loading strategy costs. Objective Exploring cost/effectiveness of AHSCT and high-efficacy disease-modifying treatments (HE-DMTs) in RR-MS, estimating costs at our centre Italy, where National Health Service (NHS) provides universal health coverage. Methods Costs (including drugs, inpatient/outpatient management) with HE-DMTs were calculated as NHS expenditures over 2- 5-year periods. Cost-effectiveness each was estimated “cost needed to treat” (CNT), i.e. expense prevent relapses, progression, or disease activity (NEDA) one patient n -years, retrieving outcomes from published studies. Results similar 2 years, whereas cheaper than most 5 years (€46 600 vs €93 800, respectively). When cost-effectiveness treatments, mean CNT NEDA twofold that AHSCT, it relapses disability. Differences remarkable especially NEDA, being €382 800 €74 900 AHSCT. Conclusions may be cost-effective selected aggressive RR-MS. Besides priceless benefits treated individuals, cost-savings generated by contribute improving healthcare assistance population level.

Language: Английский

Citations

1
Autoimmune Disease DOI Creative Commons
Tobias Alexander, Basil Sharrack,

Montserrat Rovira

et al.

Springer eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 825 - 836

Published: Jan. 1, 2024

Language: Английский

Citations

1
Neuropsychological outcomes following HSCT in MS: A Systematic Review DOI
Laura Davenport,

Mathew McCauley,

Erin Breheny

et al.

Multiple Sclerosis and Related Disorders, Journal Year: 2024, Volume and Issue: 88, P. 105702 - 105702

Published: June 5, 2024

Language: Английский

Citations

1